The great medicines scandal: Access is not just about cost

doi:10.1136/bmj.333.7557.44-a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Brenda J Waning (bwaning@bu.edu), assistant professor of international health

Boston University School of Public Health, Boston, MA 02118, USA

EDITOR—I write with reference to the editorial by Richards.1 In addition to important information on pricing, the World Health Organization/Health Action International report provides vital information on the availability of medicines in low resource settings. The authors report alarmingly low availability of key medicines to treat chronic diseases in both public and private pharmacies across most regions.

For example, hydrochlorothiazide, …